🇺🇸 FDA
Patent

US 11236175

T cell modifying compounds and uses thereof

granted A61KA61K35/26A61K40/11

Quick answer

US patent 11236175 (T cell modifying compounds and uses thereof) held by Sangamo Therapeutics, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K35/26, A61K40/11, A61K40/31, A61K40/4205